AMRI names quality control director for troubled plant, following lead of J&J, Novartis, others

Another pharmaceutical manufacturer has announced that it is beefing up quality control management after running afoul of FDA inspectors. AMRI ($AMRI) has named Tom McGrath as director of quality for aseptic services at its Burlington, MA, facility, which last year was cited in an FDA warning letter. A string of companies including Johnson & Johnson ($JNJ), Novartis ($NVS) and Hospira ($HSP) have recently named new leaders ranging from the plant level to the executive suite, whose focus, at least in part, will be on improving GMP in plants. Release | Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.